| Company Name: |
Labnetwork lnc. |
| Tel: |
+86-27-50766799 +86-18062016861 |
| Email: |
contact@labnetwork.com |
| Company Name: |
Energy Chemical |
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing@energy-chemical.com |
|
| | 4-HYDROXYALPRAZOLAM Basic information |
| | 4-HYDROXYALPRAZOLAM Chemical Properties |
| Melting point | 160-1620C | | Boiling point | 559.2±60.0 °C(Predicted) | | density | 1.45±0.1 g/cm3(Predicted) | | storage temp. | Controlled Substance, -20°C Freezer | | solubility | DMSO: 8 mg/ml | | form | White solid. | | pka | 11.59±0.40(Predicted) |
| | 4-HYDROXYALPRAZOLAM Usage And Synthesis |
| Description | Alprazolam is a benzodiazepine with anxiolytic and sedative actions. 4-Hydroxyalprazolam is a major metabolite of alprazolam, produced by the actions of cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5. It may be detected in serum or, in a glucuronidated form, in urine. Alternatively, 4-hydroxyalprazolam can be further metabolized to benzophenone. | | Chemical Properties | White Solid | | Uses | A metabolite of Alprazolam, a benzodiazepine.
Controlled Substance | | Definition | ChEBI: 4-Hydroxyalprazolam is a triazolobenzodiazepine. | | References | [1] NORIKO HIROTA. In Vitro/in Vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans[J]. Biopharmaceutics & Drug Disposition, 2001, 22 2: 53-71. DOI: 10.1002/bdd.261
[2] J ANDREW WILLIAMS. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.[J]. Drug Metabolism and Disposition, 2002, 20 1: 883-891. DOI: 10.1124/dmd.30.8.883 |
| | 4-HYDROXYALPRAZOLAM Preparation Products And Raw materials |
|